Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
Jaehnig EJ, Fernandez-Martinez A, Vashist TD, Holt MV, Williams L, Lei JT, Moon CI, Kim BJ, Dou Y, Zhao H, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Perou CM, Carey LA, Robles AI, Hyslop T, Wen Y, McCart L, Krek A, Petralia F, Miles G, Kavuri SM, Gillette MA, Mani DR, Carr SA, Zhang B, Ellis MJ, Satpathy S, Anurag M.
Jaehnig EJ, et al. Among authors: robles ai.
Cell Rep Med. 2025 Jun 17;6(6):102154. doi: 10.1016/j.xcrm.2025.102154. Epub 2025 Jun 5.
Cell Rep Med. 2025.
PMID: 40480221
Free article.
Clinical Trial.